Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Generate Biomedicines official news-release RSS · 行业原文收录 · 来源发布:Tue Oct 13 2026 20:30:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Tue Oct 13 2026 21:08:11 GMT+0000 (Coordinated Universal Time)
已保存的原文节选
Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will receive $30M upfront, up to $35M in early preclinical milestones, and a total of up to $1.2B in milestones, plus tiered royalties for two initial programs, with an option to add a third
以上为带出处的原文节选,完整内容请阅读原始链接。自动收录与主题分类不等于事实核验。